GLPwatch
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
NCT03087032 · Recruiting
Last updated 2026-05-28This clinical trial compares two diabetes treatments—liraglutide and glargine—given as injections in overweight or obese adults with type 2 diabetes to see which helps more patients reach healthy blood sugar levels without causing low blood sugar or weight gain.
What this study is testing ClinicalTrials.gov NCT03087032 ↗
Description as written by the study sponsor.
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Treatments tested
- Liraglutide also known as Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate Drug
Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
- insulin glargine also known as Lantus Drug
Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
| Main thing measured | the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3% |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Conditions studied | Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic) |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03087032 ↗